Experience with gemcitabine and cisplatin in the therapy of inoperable and metastatic cholangiocarcinoma

World Journal of Gastroenterology

Volumn 13, Issue 20, 2007, Pages 2852-2854

  Charoentum, Chalyut ^a   Thongprasert, Sumitra ^a   Chewaskulyong, Busyamas ^a   Munprakan, Sutthirak ^a  

^a CHIANG MAI UNIVERSITY   (Thailand)

Author keywords

Cholangiocarcinoma; Cisplatin; Gemcitabine

Indexed keywords

CISPLATIN; DEXAMETHASONE; GEMCITABINE; MANNITOL; ONDANSETRON;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT CARCINOMA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INOPERABLE CANCER; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; RETROSPECTIVE STUDY; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA;

EID: 34347214432     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v13.i20.2852     Document Type: Article

References (11)

1. Falkson G, MacIntyre JM, Moertel CG. Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer 1984; 54: 965-969
2. Takada T, Kato H, Matsushiro T, Nimura Y, Nagakawa T, Nakayama T. Comparison of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas. Oncology 1994; 51: 396-400
3. Choi CW, Choi IK, Seo JH, Kim BS, Kim JS, Kim CD, Um SH, Kim JS, Kim YH. Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. Am J Clin Oncol 2000; 23: 425-428
4. Kubicka S, Rudolph KL, Tietze MK, Lorenz M, Manns M. Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepatogastroenterology 2001; 48: 783-789
5. Penz M, Kornek GV, Raderer M, Ulrich-Pur H, Fiebiger W, Lenauer A, Depisch D, Krauss G, Schneeweiss B, Scheithauer W. Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol 2001; 12: 183-186
6. Thongprasert S, Napapan S, Charoentum C, Moonprakan S. Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol 2005; 16: 279-281
7. Park BK, Kim YJ, Park JY, Bang S, Park SW, Chung JB, Kim KS, Choi JS, Lee WJ, Song SY. Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. J Gastroenterol Hepatol 2006; 21: 999-1003
8. Kim ST, Park JO, Lee J, Lee KT, Lee JK, Choi SH, Hec, JS, Park YS, Kang WK, Park K. A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Cancer 2006; 106: 1339-1346
9. Andre T, Tournigand C, Rosmorduc O, Provent S, Maindrault-Goebel F, Avenin D, Selle F, Paye F, Hannoun L, Houry S, Gayet B, Lotz JP, de Gramont A, Louvet C. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 2004; 15: 1339-1343
10. Cho JY, Paik YH, Chang YS, Lee SJ, Lee DK, Song SY, Chung JB, Park MS, Yu JS, Yoon DS. Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic bihary tract carcinoma. Cancer 2005; 104: 2753-2758
11. Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, Donehower RC, Fitch T, Picus J, Erlichman C. Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol 2006; 24: 3069-3074